Investigating ways to reverse chronic lung scarring caused by aging cells
Official title: Targeting Senescence Specific Mechanisms of NF-κB Activation to Reverse Chronic Pulmonary Fibrosis
Funded at Mayo Clinic Rochester · NIH-11076654 · Data updated 2026-11-12
This study is looking at how certain aging cells in the lungs affect idiopathic pulmonary fibrosis (IPF) and is testing a new compound called F-4N that might help clear these cells and improve lung health for people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | May 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $530,118 |
| NIH project number | 5R01HL167796-02 |
| Project ID | NIH-11076654 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis, particularly those experiencing accelerated aging symptoms in their lungs.
✕Less likely to help
Patients with other forms of lung disease or those not diagnosed with idiopathic pulmonary fibrosis may not benefit from this research.
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF), a serious lung disease characterized by scarring and limited treatment options. The study aims to understand how certain aging cells in the lungs contribute to this condition and explores the use of a novel flavonoid compound, F-4N, which has shown promise in clearing these aging cells and reducing lung fibrosis in animal models. By targeting specific signaling pathways involved in cell aging, the research seeks to develop effective therapies for patients suffering from IPF.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve lung function and quality of life for patients with chronic pulmonary fibrosis.
How similar studies have gone: Previous research has shown success with similar approaches targeting senescent cells in other conditions, indicating potential for this novel treatment strategy.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Haak, Andrew Jon — Mayo Clinic Rochester
- Study coordinator: Haak, Andrew Jon
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.